"We continue to expect U.S. Food and Drug Administration (FDA) approval of AcelRx Pharmaceuticals Inc.'s Zalviso at/near the July Prescription Drug User Fee Act (PDUFA) date with revenue potential of +$500M. . .if it is approved at the July PDUFA, it could be shipped by year end. A 3-month delay for chemistry, manufacturing and controls/logistical reasons is possible but a 2015 full launch either way.
AcelRx Pharmaceuticals Inc. fits our top pick profile in the